Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2015 (2015), Article ID 189135, 9 pages
http://dx.doi.org/10.1155/2015/189135
Review Article

Iodine-131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective

Department of Nuclear Medicine, Kanazawa University Hospital, 13-1 Takara-machi, Kanazawa, Ishikawa 920-8641, Japan

Received 24 June 2014; Accepted 1 August 2014

Academic Editor: Takahiro Higuchi

Copyright © 2015 Daiki Kayano and Seigo Kinuya. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. M. Maris, “Recent advances in neuroblastoma,” The New England Journal of Medicine, vol. 362, no. 23, pp. 2154–2211, 2010. View at Google Scholar · View at Scopus
  2. W. B. London, R. P. Castleberry, K. K. Matthay et al., “Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group,” Journal of Clinical Oncology, vol. 23, no. 27, pp. 6459–6465, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. M. Maris, M. D. Hogarty, R. Bagatell, and S. L. Cohn, “Neuroblastoma,” The Lancet, vol. 369, no. 9579, pp. 2106–2120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. G. M. Brodeur, J. Pritchard, F. Berthold et al., “Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment,” Journal of Clinical Oncology, vol. 11, no. 8, pp. 1466–1477, 1993. View at Google Scholar · View at Scopus
  5. M. A. Smith, N. L. Seibel, S. F. Altekruse et al., “Outcomes for children and adolescents with cancer: challenges for the twenty-first century,” Journal of Clinical Oncology, vol. 28, no. 15, pp. 2625–2634, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. D. M. Wieland, J. I. Wu, and L. E. Brown, “Radiolabeled adrenergic neuron-bocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine,” Journal of Nuclear Medicine, vol. 21, no. 4, pp. 349–353, 1980. View at Google Scholar · View at Scopus
  7. M. Nakajo, B. Shapiro, J. Copp et al., “The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy,” Journal of Nuclear Medicine, vol. 24, no. 8, pp. 672–682, 1983. View at Google Scholar · View at Scopus
  8. D. M. Wieland, L. E. Brown, M. C. Tobes et al., “Imaging the primate adrenal medulla with [123I] and [131I] meta-iodobenzylguanidine: concise communication,” Journal of Nuclear Medicine, vol. 22, no. 4, pp. 358–364, 1981. View at Google Scholar · View at Scopus
  9. E. Bombardieri, F. Giammarile, C. Aktolun et al., “131I/123I-Metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 12, pp. 2436–2446, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Sisson, B. Shapiro, W. H. Beierwaltes et al., “Treatment of malignant pheochromocytoma with a new radiopharmaceutical,” Transactions of the Association of American Physicians, vol. 96, pp. 209–217, 1983. View at Google Scholar · View at Scopus
  11. J. Treuner, T. Klingebiel, U. Feine et al., “Clinical experiences in the treatment of neuroblastoma with 131I-metaiodobenzylguanidine,” Pediatric Hematology and Oncology, vol. 3, no. 3, pp. 205–216, 1986. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Jaques Jr., M. C. Tobes, J. C. Sisson, J. A. Baker, and D. M. Wieland, “Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells,” Molecular Pharmacology, vol. 26, no. 3, pp. 539–546, 1984. View at Google Scholar · View at Scopus
  13. S. Jacques Jr., M. C. Tobes, and J. C. Sisson, “Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one,” Cancer Research, vol. 47, no. 15, pp. 3920–3928, 1987. View at Google Scholar · View at Scopus
  14. J. Buck, G. Bruchelt, R. Girgert, J. Treuner, and D. Niethammer, “Specific uptake of m-[125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH,” Cancer Research, vol. 45, no. 12, pp. 6366–6370, 1985. View at Google Scholar · View at Scopus
  15. M. C. Tobes, S. Jaques Jr., D. M. Wieland, and J. C. Sisson, “Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine,” Journal of Nuclear Medicine, vol. 26, no. 8, pp. 897–907, 1985. View at Google Scholar · View at Scopus
  16. L. A. Smets, C. Loesberg, M. Janssen, E. A. Metwally, and R. Huiskamp, “Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells,” Cancer Research, vol. 49, no. 11, pp. 2941–2944, 1989. View at Google Scholar · View at Scopus
  17. B. L. Shulkin and B. Shapiro, “Current concepts on the diagnostic use of MIBG in children,” Journal of Nuclear Medicine, vol. 39, no. 4, pp. 679–688, 1998. View at Google Scholar · View at Scopus
  18. L. S. Lashford, J. P. Hancock, and J. T. Kemshead, “Meta-iodobenzylguanidine (mIBG) uptake and storage in the human neuroblastoma cell line SK-N-BE(2C),” International Journal of Cancer, vol. 47, no. 1, pp. 105–109, 1991. View at Publisher · View at Google Scholar · View at Scopus
  19. M. N. Gaze, I. M. Huxham, R. J. Mairs, and A. Barrett, “Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging,” International Journal of Cancer, vol. 47, no. 6, pp. 875–880, 1991. View at Google Scholar · View at Scopus
  20. F. Giammarile, A. Chiti, M. Lassmann, B. Brans, and G. Flux, “EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 5, pp. 1039–1047, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Nakajo, K. Yoshinaga, N. Oriuchi, S. Kinuya, K. Yokoyama, and T. Yamaguchi, “Guideline draft of appropriate use of 131I-MIBG for internal radiotherapy of neuroendocrine tumors,” Kaku Igaku, vol. 45, no. 1, supplement, pp. 1–40, 2008. View at Google Scholar · View at Scopus
  22. G. Bleeker, R. A. Schoot, H. N. Caron et al., “Toxicity of upfront 131I-metaiodobenzylguanidine (131I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, no. 11, pp. 1711–1717, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Modak, N. Pandit-Taskar, B. H. Kushner et al., “Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy,” Pediatric Blood and Cancer, vol. 50, no. 6, pp. 1271–1273, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. M. A. Kosmin, J. B. Bomanji, N. J. Cork, A. Shankar, and M. N. Gaze, “Hypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastoma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 4, pp. 597–601, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Wong, K. K. Matthay, W. J. Boscardin, R. A. Hawkins, P. R. Brakeman, and S. G. Dubois, “Acute changes in blood pressure in patients with neuroblastoma treated with 131I-metaiodobenzylguanidine (MIBG),” Pediatric Blood and Cancer, vol. 60, no. 9, pp. 1424–1430, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. S. G. DuBois, J. Messina, J. M. Maris et al., “Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma,” Journal of Clinical Oncology, vol. 22, no. 12, pp. 2452–2460, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. K. K. Matthay, G. Yanik, J. Messina et al., “Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma,” Journal of Clinical Oncology, vol. 25, no. 9, pp. 1054–1060, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. K. K. Matthay, K. DeSantes, B. Hasegawa et al., “Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma,” Journal of Clinical Oncology, vol. 16, no. 1, pp. 229–236, 1998. View at Google Scholar · View at Scopus
  29. K. K. Matthay, J. C. Tan, J. G. Villablanca et al., “Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study,” Journal of Clinical Oncology, vol. 24, no. 3, pp. 500–506, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. K. K. Matthay, A. Quach, J. Huberty et al., “Iodine-131-metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study,” Journal of Clinical Oncology, vol. 27, no. 7, pp. 1020–1025, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. S. C. Clement, B. L. van Eck-Smit, A. S. van Trotsenburg, L. C. Kremer, G. A. Tytgat, and H. M. van Santen, “Long-term follow-up of the thyroid gland after treatment with 131I-Metaiodobenzylguanidine in children with neuroblastoma: importance of continuous surveillance,” Pediatric Blood and Cancer, vol. 60, no. 11, pp. 1833–1838, 2013. View at Publisher · View at Google Scholar
  32. A. Garaventa, C. Gambini, G. Villavecchia et al., “Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine,” Cancer, vol. 97, no. 5, pp. 1332–1338, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. B. Weiss, A. Vora, J. Huberty, R. A. Hawkins, and K. K. Matthay, “Secondary myelodysplastic syndrome and leukemia following 131I-metaiodobenzylguanidine therapy for relapsed neuroblastoma,” Journal of Pediatric Hematology/Oncology, vol. 25, no. 7, pp. 543–547, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Lumbroso, O. Hartmann, and M. Schlumberger, “Therapeutic use of [131I]metaiodobenzylguanidine in neuroblastoma: a phase II study in 26 patients,” Journal of Nuclear Biology and Medicine, vol. 35, no. 4, pp. 220–223, 1991. View at Google Scholar · View at Scopus
  35. R. J. Hutchinson, J. C. Sisson, B. Shapiro et al., “131-I-metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma,” The American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 15, no. 3, pp. 226–232, 1992. View at Google Scholar · View at Scopus
  36. K. K. Matthay, J. P. Huberty, R. S. Hattner et al., “Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma,” Journal of Nuclear Biology and Medicine, vol. 35, no. 4, pp. 244–247, 1991. View at Google Scholar · View at Scopus
  37. T. Klingebiel, U. Feine, J. Treuner, P. Reuland, R. Handgretinger, and D. Niethammer, “Treatment of neuroblastoma with [131I]metaiodobenzylguanidine: long-term results in 25 patients,” Journal of Nuclear Biology and Medicine, vol. 35, no. 4, pp. 216–219, 1991. View at Google Scholar · View at Scopus
  38. A. Garaventa, O. Bellagamba, M. S. Lo Piccolo et al., “131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients,” British Journal of Cancer, vol. 81, no. 8, pp. 1378–1384, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Claudiani, A. Garaventa, L. Bertolazzi et al., “[131I]metaiodobenzylguanidine therapy in advanced neuroblastoma,” Journal of Nuclear Biology and Medicine, vol. 35, no. 4, pp. 224–227, 1991. View at Google Scholar · View at Scopus
  40. M. R. Castellani, A. Chiti, E. Seregni, and E. Bombardieri, “Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours: experience of the National Cancer Institute of Milan,” Quarterly Journal of Nuclear Medicine, vol. 44, no. 1, pp. 77–87, 2000. View at Google Scholar · View at Scopus
  41. T. I. Kang, P. Brophy, M. Hickeson et al., “Targeted radiotherapy with submyeloablative doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma,” Journal of Pediatric Hematology/Oncology, vol. 25, no. 10, pp. 769–773, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. C. A. Hoefnagel, P. A. Voute, J. de Kraker, and R. A. Valdes Olmos, “[131I]metaiodobenzylguanidine therapy after conventional therapy for neuroblastoma,” Journal of Nuclear Biology and Medicine, vol. 35, no. 4, pp. 202–206, 1991. View at Google Scholar · View at Scopus
  43. M. W. Ben-Arush, A. B. Barak, R. Bar-Deroma et al., “Targeted therapy with low doses of 131I-MIBG is effective for disease palliation in highly refractory neuroblastoma,” Israel Medical Association Journal, vol. 15, no. 1, pp. 31–34, 2013. View at Google Scholar · View at Scopus
  44. K. Johnson, B. McGlynn, J. Saggio et al., “Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma,” Pediatric Blood and Cancer, vol. 57, no. 7, pp. 1124–1129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. R. Mastrangelo, A. Tornesello, R. Riccardi et al., “A new approach in the treatment of stage IV neuroblastoma using a combination of [131I]meta-iodobenzylguanidine (MIBG) and cisplatin,” European Journal of Cancer, vol. 31, no. 4, pp. 606–611, 1995. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Mastrangelo, A. Tornesello, L. Diociaiuti et al., “Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy,” British Journal of Cancer, vol. 84, no. 4, pp. 460–464, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. M. N. Gaze, Y. Chang, G. D. Flux, R. J. Mairs, F. H. Saran, and S. T. Meller, “Feasibility of dosimetry-based high-dose 131I-meta- iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma,” Cancer Biotherapy and Radiopharmaceuticals, vol. 20, no. 2, pp. 195–199, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. S. G. DuBois, L. Chesler, S. Groshen et al., “Phase I study of vincristine, irinotecan, and 131I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial,” Clinical Cancer Research, vol. 18, no. 9, pp. 2679–2686, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. S. S. More, M. Itsara, X. Yang et al., “Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems,” Clinical Cancer Research, vol. 17, no. 8, pp. 2339–2349, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. F. Berthold, J. Boos, S. Burdach et al., “Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial,” The Lancet Oncology, vol. 6, no. 9, pp. 649–658, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. G. A. Yanik, J. E. Levine, K. K. Matthay et al., “Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma,” Journal of Clinical Oncology, vol. 20, no. 8, pp. 2142–2149, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. S. French, S. G. Dubois, B. Horn et al., “131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma,” Pediatric Blood and Cancer, vol. 60, no. 5, pp. 879–884, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. K. K. Matthay, R. C. Seeger, C. P. Reynolds et al., “Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the Childrens Cancer Group,” Journal of Clinical Oncology, vol. 12, no. 11, pp. 2382–2389, 1994. View at Google Scholar · View at Scopus
  54. R. Ladenstein, C. Lasset, O. Hartmann et al., “Comparison of auto versus allografting as consolidation of primary treatments in advanced neuroblastoma over one year of age at diagnosis: report from the European Group for Bone Marrow Transplantation,” Bone Marrow Transplantation, vol. 14, no. 1, pp. 37–46, 1994. View at Google Scholar · View at Scopus
  55. K. Goi, T. Inukai, H. Honna et al., “Successful tandem (autologous-cord blood) SCT in advanced neuroblastomas with highly amplified MYCN,” Bone Marrow Transplantation, vol. 46, no. 6, pp. 835–839, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Inoue, T. Nakano, A. Yoneda et al., “Graft-versus-tumor effect in a patient with advanced neuroblastoma who received HLA haplo-identical bone marrow transplantation,” Bone Marrow Transplantation, vol. 32, no. 1, pp. 103–106, 2003. View at Publisher · View at Google Scholar · View at Scopus
  57. A. Marabelle, C. Paillard, A. Tchirkov et al., “Graft-versus-tumour effect in refractory metastatic neuroblastoma,” Bone Marrow Transplantation, vol. 39, no. 12, pp. 809–810, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. Y. Sato, H. Kurosawa, K. Fukushima et al., “I-131-metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma,” Italian Journal of Pediatrics, vol. 38, no. 1, article 53, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. H. Takahashi, A. Manabe, C. Aoyama et al., “Iodine-131-metaiodobenzylguanidine therapy with reduced-intensity allogeneic stem cell transplantation in recurrent neuroblastoma,” Pediatric Blood and Cancer, vol. 50, no. 3, pp. 676–678, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Cornelissen, A. B. van Kuilenburg, L. Elzinga et al., “Hyperbaric oxygen enhances the effects of meta-iodobenzylguanidine (MIBG) on energy metabolism and lipid peroxidation in the human neuroblastoma cell line SK-N-BE(2C),” Anticancer Research, vol. 17, no. 1A, pp. 259–264, 1997. View at Google Scholar · View at Scopus
  61. P. A. Voute, A. J. van der Kleij, J. de Kraker, C. A. Hoefnagel, M. M. C. Tiel-Van Buul, and H. van Gennip, “Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV,” European Journal of Cancer A: General Topics, vol. 31, no. 4, pp. 596–600, 1995. View at Publisher · View at Google Scholar · View at Scopus
  62. J. de Kraker, K. A. Hoefnagel, A. C. Verschuur, B. van Eck, H. M. van Santen, and H. N. Caron, “Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age,” European Journal of Cancer, vol. 44, no. 4, pp. 551–556, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Schmidt, T. Simon, B. Hero et al., “Is there a benefit of 131I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of the German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004,” NuklearMedizin, vol. 45, no. 4, pp. 145–151, 2006. View at Google Scholar · View at Scopus
  64. S. Mastrangelo, V. Rufini, A. Ruggiero, A. Di Giannatale, and R. Riccardi, “Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of 131I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen,” Pediatric Blood & Cancer, vol. 56, no. 7, pp. 1032–1040, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. R. A. Schoot, G. Bleeker, H. N. Caron et al., “The role of 131I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 40, no. 10, pp. 1516–1522, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. R. J. Mairs, S. H. Cunningham, J. Russell et al., “No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation,” Journal of Nuclear Medicine, vol. 36, no. 6, pp. 1088–1095, 1995. View at Google Scholar · View at Scopus
  67. G. Vaidyanathan and M. R. Zalutsky, “No-carrier-added synthesis of meta-[131I]iodobenzylguanidine,” Applied Radiation and Isotopes, vol. 44, no. 3, pp. 621–628, 1993. View at Publisher · View at Google Scholar · View at Scopus
  68. J. A. Barrett, J. L. Joyal, S. M. Hillier et al., “Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution,” Cancer Biotherapy and Radiopharmaceuticals, vol. 25, no. 3, pp. 299–308, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. R. E. Coleman, J. B. Stubbs, J. A. Barrett, M. de La Guardia, N. Lafrance, and J. W. Babich, “Radiation dosimetry, pharmacokinetics, and safety of ultratrace iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid,” Cancer Biotherapy and Radiopharmaceuticals, vol. 24, no. 4, pp. 469–475, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. K. K. Matthay, B. Weiss, J. G. Villablanca et al., “Dose escalation study of no-carrier-added 131I- metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trial,” Journal of Nuclear Medicine, vol. 53, no. 7, pp. 1155–1163, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. J. L. Humm, “Dosimetric aspects of radiolabeled antibodies for tumor therapy,” Journal of Nuclear Medicine, vol. 27, no. 9, pp. 1490–1497, 1986. View at Google Scholar · View at Scopus
  72. J. C. Sisson, R. J. Hutchinson, B. Shapiro et al., “Iodine-125-MIBG to treat neuroblastoma: preliminary report,” Journal of Nuclear Medicine, vol. 31, no. 9, pp. 1479–1485, 1990. View at Google Scholar · View at Scopus
  73. R. W. Howell, V. R. Narra, K. S. R. Sastry, and D. V. Rao, “On the equivalent dose for auger electron emitters,” Radiation Research, vol. 134, no. 1, pp. 71–78, 1993. View at Publisher · View at Google Scholar · View at Scopus
  74. W. Weber, J. Weber, and R. Senekowitsch-Schmidtke, “Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes,” Cancer Research, vol. 56, no. 23, pp. 5428–5434, 1996. View at Google Scholar · View at Scopus
  75. J. C. Sisson, B. Shapiro, R. J. Hutchinson, B. L. Shulkin, and S. Zempel, “Survival of patients with neuroblastoma treated with 125-I MIBG,” The American Journal of Clinical Oncology, vol. 19, no. 2, pp. 144–148, 1996. View at Publisher · View at Google Scholar · View at Scopus
  76. W. H. Y. Roa, G. G. Miller, A. J. B. McEwan et al., “Targeted radiotherapy of multicell neuroblastoma spheroids with high specific activity [125I]meta-iodobenzylguanidine,” International Journal of Radiation Oncology, Biology, Physics, vol. 41, no. 2, pp. 425–432, 1998. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Bardiès and P. Pihet, “Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy,” Current Pharmaceutical Design, vol. 6, no. 14, pp. 1433–1455, 2000. View at Publisher · View at Google Scholar · View at Scopus
  78. M. R. Zalutsky, D. A. Reardon, G. Akabani et al., “Clinical experience with alpha-particle-emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6,” Journal of Nuclear Medicine, vol. 49, no. 1, pp. 30–38, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. D. K. Strickland, G. Vaidyanathan, and M. R. Zalutsky, “Cytotoxicity of α-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells,” Cancer Research, vol. 54, no. 20, pp. 5414–5419, 1994. View at Google Scholar · View at Scopus
  80. S. H. Cunningham, R. J. Mairs, T. E. Wheldon, P. C. Welsh, G. Vaidyanathan, and M. R. Zalutsky, “Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions,” British Journal of Cancer, vol. 77, no. 12, pp. 2061–2068, 1998. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Boyd, S. C. Ross, J. Dorrens et al., “Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with α-, β-, and auger electron-emitting radionuclides,” Journal of Nuclear Medicine, vol. 47, no. 6, pp. 1007–1015, 2006. View at Google Scholar · View at Scopus